title: Efficacy and safety of perampanel in the subgroup of elderly patients included in the phase III epilepsy clinical trials.
abstract: Clinical data regarding use of antiepileptic drugs in the elderly are generally scarce. Therefore, a subanalysis of subjects aged ≥ 65 years who participated in the 3 phase III perampanel studies was undertaken to determine efficacy and safety in these patients. Efficacy (change in seizure frequency/28 days and 50% responder rate) in the elderly subgroup was found to be consistent with the adult population. Adverse event rates were also largely similar, with some exceptions. Because risks of falls, dizziness, and fatigue were greater in the elderly, careful titration of perampanel in patients aged ≥ 65 years is suggested, especially at higher doses, where balancing tolerability and clinical response is necessary.
authors.affiliation: Department of Neurology and College of Pharmacy, University of Minnesota, Minneapolis, MN, USA. Electronic address: leppi001@umn.edu.
authors.forename: Ilo E
authors.initials: IE
authors.lastname: Leppik
authors.affiliation: Consultants in Epilepsy & Neurology PLLC, Boise, ID, USA. Electronic address: rtw@idahoepilepsy.com.
authors.forename: Robert T
authors.initials: RT
authors.lastname: Wechsler
authors.affiliation: Eisai Medical and Scientific Affairs, Woodcliff Lake, NJ, USA. Electronic address: betsy_williams@eisai.com.
authors.forename: Betsy
authors.initials: B
authors.lastname: Williams
authors.affiliation: Eisai Neuroscience and General Medicine PCU, Woodcliff Lake, NJ, USA. Electronic address: Haichen_Yang@eisai.com.
authors.forename: Haichen
authors.initials: H
authors.lastname: Yang
authors.affiliation: Eisai Medical and Scientific Affairs, Woodcliff Lake, NJ, USA. Electronic address: Xiaozheng_Zhou@eisai.com.
authors.forename: Sharon
authors.initials: S
authors.lastname: Zhou
authors.affiliation: Eisai Neuroscience and General Medicine PCU, Woodcliff Lake, NJ, USA. Electronic address: Antonio_Laurenza@eisai.com.
authors.forename: Antonio
authors.initials: A
authors.lastname: Laurenza
mesh_terms: D000368:Aged; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D004827:Epilepsy / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D015337:Multicenter Studies as Topic; D009570:Nitriles; D011728:Pyridones / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D000927:Anticonvulsants; D009570:Nitriles; D011728:Pyridones; C551441:perampanel
keywords: Adverse effects; Antiepileptic drugs; Efficacy; Elderly; Perampanel